8-K: Longeveron Gets Nasdaq Extension on Bid Price Rule

Longeveron Inc. received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement.

Summary

• Longeveron Inc. (LGVN) previously received a notice on September 22, 2025, for non-compliance with Nasdaq's $1.00 minimum bid price requirement (Rule 5550(a)(2)).
• The company's Class A common stock had traded below $1.00 for thirty consecutive business days.
• The initial compliance period was 180 calendar days, ending March 23, 2026.
• On March 24, 2026, Nasdaq granted an additional 180-day extension, pushing the new deadline to September 21, 2026.
• To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days before September 21, 2026.
• The notice has no immediate effect on the company's listing status on The Nasdaq Capital Market.
• Longeveron intends to monitor its stock price and assess options, including a potential reverse stock split, to regain compliance.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive development, as the extension avoids immediate delisting but does not resolve the underlying issue of non-compliance with the minimum bid price requirement. The need for a potential reverse stock split indicates ongoing challenges.

Positives

• Nasdaq granted an additional 180-day extension, providing more time to regain compliance.
• The company's listing on The Nasdaq Capital Market remains fully effective without immediate delisting.

Negatives

• The company remains non-compliant with Nasdaq's $1.00 minimum bid price requirement.
• The stock price has been below $1.00 for an extended period, indicating potential investor concern or operational challenges.

Risks

• There is no assurance that the company will regain compliance with the Minimum Bid Price Requirement by September 21, 2026.
• Failure to regain compliance could lead to delisting from The Nasdaq Capital Market.
• The company may need to effect a reverse stock split, which can sometimes be perceived negatively by investors.
• There is no assurance of compliance with other Nasdaq listing requirements.

Future Outlook

The company intends to monitor its common stock's closing bid price and evaluate available options, including a reverse stock split if necessary, to regain compliance and maintain its Nasdaq listing. However, there is no assurance that compliance will be regained or that other Nasdaq listing requirements will be met.

Management Comments

• "The Company intends to monitor the closing bid price of its Common Stock and assess its available options in order to regain compliance with the Minimum Bid Price Requirement and continue listing on The Nasdaq Capital Market, including by effecting a reverse stock split, if necessary."

Industry Context

StockSavvy.ai notes that maintaining a minimum bid price is a standard Nasdaq listing requirement designed to ensure a certain level of market stability and investor confidence. Companies often face this challenge, especially smaller biopharmaceutical firms, and extensions are common, providing a temporary reprieve but not resolving the underlying issue of low stock valuation.

Stakeholder Impact

• Shareholders: Potential for continued uncertainty regarding the stock's listing status; risk of dilution if a reverse stock split is implemented without a corresponding increase in market value.
• Investors: The extension provides a temporary relief from immediate delisting concerns, but the underlying issue of low stock price persists, potentially impacting investor confidence.

Next Steps

• Monitor the closing bid price of the Common Stock.
• Assess available options to regain compliance, including a potential reverse stock split.
• Achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before September 21, 2026.

Key Dates

Recommendation

While the extension from Nasdaq provides a temporary reprieve from immediate delisting, the underlying issue of the stock trading below $1.00 remains. The company's intention to consider a reverse stock split indicates ongoing challenges. Investors should hold to monitor the company's progress in regaining compliance and assess the impact of any potential corporate actions, as the situation remains uncertain.

Keywords

Longeveron, LGVN, Nasdaq, delisting, minimum bid price, stock compliance, reverse stock split, SEC filing, 8-K, capital market